Ocular Therapeutics Announces 80% Rescue-Free Rate In U.S. Wet AMD Study, Promising Diabetic Retinopathy Results, And FDA Special Protocol Assessment For SOL-one Study; Highlights Significant Market Potential And Strong Team Of Retina Experts
Ocular Therapeutics Announces 80% Rescue-Free Rate In U.S. Wet AMD Study, Promising Diabetic Retinopathy Results, And FDA Special Protocol Assessment For SOL-one Study; Highlights Significant Market Potential And Strong Team Of Retina Experts
Ocular Therapeutics宣佈在美國患有溼性年齡相關黃斑變性的病人中達到了80%的免救護率，並有望在糖尿病性視網膜病變方面取得良好的結果，而FDA還對SOL-one研究項目進行了特別協議評估，凸顯了該領域巨大的市場潛力和專業的視網膜專家團隊。
Ocular Therapeutics Announces 80% Rescue-Free Rate In U.S. Wet AMD Study, Promising Diabetic Retinopathy Results, And FDA Special Protocol Assessment For SOL-one Study; Highlights Significant Market Potential And Strong Team Of Retina Experts
Ocular Therapeutics宣佈在美國患有溼性年齡相關黃斑變性的病人中達到了80%的免救護率，並有望在糖尿病性視網膜病變方面取得良好的結果，而FDA還對SOL-one研究項目進行了特別協議評估，凸顯了該領域巨大的市場潛力和專業的視網膜專家團隊。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。